Physician profile
Joseph Meschi
NPI 1942295530
$397.72
in general payments reported to CMS, 2019-2025
11 companies · $91.10 in 2025
The $91.10 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.95 · 2021: $74.51 · 2022: $16.45 · 2023: $46.31 · 2024: $69.40 · 2025: $91.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $194 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $194.39 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $99.95 | 2020 | |
| Merck Sharp & Dohme LLC | $79.17 | 2021-2024 | Keytruda |
| Incyte Corporation | $41.08 | 2025 | Jakafi, Zynyz, Monjuvi |
| Tempus Ai, INC | $28.26 | 2024 | |
| Gilead Sciences, INC. | $24.34 | 2021-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $22.71 | 2025 | |
| Genzyme Corporation | $22.47 | 2021 | |
| Global Blood Therapeutics, INC. | $22.16 | 2021 | |
| Genentech USA, INC. | $22.00 | 2024 | Tecentriq |
| Cardinal Health 414 LLC | $20.69 | 2023 | |
| Glaxosmithkline, LLC. | $14.89 | 2025 | Jemperli, Zejula |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Meschi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.